For years, the development of drugs for respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have relied on the administration of a new drug, mostly by inhalation and assessment by physiologic tests and questionnaires. More and more these new drugs are administered in fixed combinations.
This white paper outlines the latest respiratory R&D trends encompassing outcomes and clinical trial study designs.
11-12F, Cheongryong Building, 257, Hangang-daero, Galwol-dong, Yongsan-gu, Seoul, Republic of Korea,
Seoul, Korea, Republic of